Skip to main content

Harm Reduction Models in Recovery Housing: Operational Considerations

Jeremy Bloom, Co-founder · · Updated

As of September 2026, federal grant policy and clinical standards do not say the same thing about harm reduction. Operators have to read both, and they have to keep prescribed medication separate from illegal drug use. This post does not predict how large any housing model will be.

What federal grant policy says

Executive Order 14321, signed July 24, 2025, and published at 90 FR 35817, directs the Secretary of Health and Human Services to take appropriate action to ensure that discretionary grants issued by SAMHSA for substance use disorder prevention, treatment, and recovery fund evidence-based programs and do not fund programs that fail to achieve adequate outcomes, including so-called harm reduction or safe consumption efforts that only facilitate illegal drug use and its attendant harm [1].

That is a direction about SAMHSA discretionary grants. It is not a sentence that every state license forbids naloxone, and it is not a sentence that prescribed medication for opioid use disorder is illegal drug use. Section 5(c) covers recipients of federal housing and homelessness assistance that operate drug-injection sites or safe-consumption sites, knowingly distribute drug paraphernalia, or permit the use or distribution of illicit drugs on property under their control. The Attorney General shall review whether those recipients are violating federal law, including 21 U.S.C. 856, and bring civil or criminal actions in appropriate cases. The Secretary of Housing and Urban Development, in coordination with the Attorney General, shall review whether those recipients are violating the terms of the programs under which they receive that assistance and freeze their assistance as appropriate [1]. This post does not restate a syringe-funding statute it did not open, and it does not describe Medicaid demonstration policy.

Medication, naloxone, and the ADA

The Department of Justice guidance dated April 5, 2022, says people in treatment or recovery from opioid use disorder typically have a disability under the ADA unless they are currently engaged in illegal drug use [2]. Use of prescribed medication for opioid use disorder, including methadone, buprenorphine, or naltrexone, is not illegal use of drugs when it is taken under the supervision of a licensed health care professional [2]. The guidance’s first example is a skilled nursing facility that refuses admission because a patient takes doctor-prescribed medication for opioid use disorder and that prohibits any of its patients from taking it. The guidance says that exclusion would violate the ADA [2]. A separate example is a jail that does not allow incoming inmates to continue taking medication for opioid use disorder prescribed before their detention. The guidance says that blanket policy would violate the ADA [2].

A recovery residence that writes a house rule treating prescribed medication as prohibited use is in that territory. Placement decisions have to follow the published medication policy and this legal limit. Turning someone away because they take prescribed medication for opioid use disorder, under a rule that bars it, is the exclusion in the skilled-nursing example, not a clinical matching rule [2].

NARR’s version 3.0 compendium includes a position statement that the appendix still labels a draft. The footnote says it was developed at the 2016 NARR conference and updated in the appendix for the version 3.0 standard numbers [3]. It says medication-assisted treatment is one of many viable recovery tools [3]. Owners and operators cannot legally deny admission solely because an applicant currently uses physician-prescribed medication [3]. A residence may decline a referral when it does not have the staff or services for that medication, and in those cases the referral should go to an alternative facility that may be available [3]. Residences are encouraged to keep a supply of naloxone and to train staff periodically in overdose reversal [3]. The statement does not say that NARR has created a separate harm-reduction residence level.

NARR’s levels page still describes all four levels as alcohol- and illicit-substance-free [6]. Illicit-substance-free is not the same rule as a ban on prescribed medication.

Clinical standards are not grant-eligibility rules

ASAM’s fourth-edition adult overview says the edition incorporates low-threshold addiction medication access and encourages programs to consider how to better support harm reduction [4]. That is a clinical-standards statement from ASAM. It does not override Executive Order 14321’s direction to SAMHSA on discretionary grants [1]. An operator applying for a SAMHSA discretionary grant has to read the notice of funding opportunity issued after the order. An operator writing a house medication policy has to read the ADA guidance [2].

What to document

If a portfolio includes houses with different responses to a positive drug test, each house needs its own written policy. Staff who work in more than one house need to know which policy they are under. A positive test, a naloxone administration, and an overdose response are different events. The record should say which one happened, who responded, and which policy applied.

Whether 42 CFR Part 2 applies still depends on whether the residence is, or is an identified part of, a federally assisted program [5, 7]. A program is a person, other than a general medical facility, that holds itself out as providing and provides substance use disorder diagnosis, treatment, or referral for treatment; an identified unit within a general medical facility that holds itself out as providing and provides that care; or medical personnel or other staff in a general medical facility whose primary function is that care and who are identified as those providers [7]. Many recovery residences are not part 2 programs. HIPAA applies only if the operator is a covered entity or a business associate.

A documented policy is not an audit result. This post does not claim that any setup produces a clean audit or continued funding.

Encore OS includes safety and significant-event reporting for each house and records the NARR level for each residence. State certification tracking for each residence is on the roadmap. Those records can hold the event and the NARR level. They do not decide whether a grant may fund a given model.

Sources

  1. Ending Crime and Disorder on America's Streets (Executive Order 14321, 90 FR 35817), Executive Office of the President, Federal Register. Accessed September 28, 2026.
  2. The ADA and Opioid Use Disorder, U.S. Department of Justice. Accessed September 28, 2026.
  3. NARR Standard 3.0 compendium, including the medication-assisted treatment position, National Alliance for Recovery Residences. Accessed September 28, 2026.
  4. The ASAM Criteria Fourth Edition, Volume 1 adults overview, American Society of Addiction Medicine. Accessed September 28, 2026.
  5. 42 CFR 2.12, applicability, eCFR. Accessed September 28, 2026.
  6. NARR recovery residence levels, National Alliance for Recovery Residences. Accessed September 28, 2026.
  7. 42 CFR 2.11, definitions, including program, eCFR. Accessed September 28, 2026.

Encore OS runs recovery housing in the same system as care and finance: a bed board across houses, program phases and attendance, and safety events for each house.

Recovery housing on Encore OS